FDA Draft Guidance Instructs Sponsors on Content and Timing of Diversity Plans for Clinical Trials | Troutman Pepper
For several years, FDA has advanced a policy of increasing diversity in clinical trial populations. During that time, FDA issued broad policy statements, as well as guidance on improved...
Drug Administration Safety Office Of Minority Health Office Of Inspector Improve Enrollment Underrepresented Racial Ethnic Populations
Source: jdsupra.com